Danish Hospital started a clinical trial of Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer

Naestved Hospital is enrolling patients into the clinical trial investigating Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer.

Oncological treatment of patients with disseminated non-small cell lung cancer (NSCLC) is depending on the status of programmed death-ligand 1 (PD-L1), anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), so called oncodrivers. These can be measured in pleural fluid, but the prevalence is uncertain. In a this study, investigators aim to measure PD-L1, ALK and EGFR in patients with pleural fluid cytology positive for NSCLC to report the prevalence. Also, researchers will investigate if the chance of obtaining oncodriver status is depending on the volume analysed and how the lack of oncodrivers influence the following work-up.

Participants will be recruited from patients referred to the Pleura Clinic or admitted at the ward at the Department of Respiratory Medicine, Næstved Hospital, Næstved or at the Department of Respiratory Medicine, Zealand University Hospital, Roskilde, which is the two regional centres for workup of pleural effusions. Patients will be referred from either general practice or other hospital departments.

The trial is designed to enroll male and female 18 years and older and is being conducted in the Næstved Sygehus, department of pulmonary medicine, Næstved, Region Sjælland, Denmark.

The study start date is March 15, 2021.

Among the exclusion criteria are:

  • Full oncodriver status measured in any pleural fluid in current work-up
  • Inability to understand written or spoken Danish

Further details can be found here: https://ichgcp.net/clinical-trials-registry/NCT04806412

Clinical Research News

Próximos ensaios clínicos